We are delighted to announce that Cancer & Metabolism's new 2 Year Impact Factor is 5.9, with a 5 Year Impact Factor of 6.3
Thank you to our Editors-in-Chief Dr. Michael Pollak and Dr. Matthew G. Vander Heiden for their hard work and to all those who support this journal.
Aims and scope
Cancer & Metabolism welcomes studies on all aspects of the relationship between cancer and metabolism, including:
- Molecular biology and genetics of cancer metabolism
- Whole-body metabolism, including diabetes and obesity, in relation to cancer
- Metabolomics in relation to cancer;
- Metabolism-based imaging
- Preclinical and clinical studies of metabolism-related cancer therapies.
Learn more here
Amidst an abundance of dietary advice and claims, this Collection aims to critically examine scientific evidence surrounding the impact of diet on cancer biology.
Submission deadline: 31 May 2024
This Collection seeks to unravel the intricate connections between transporters and metabolism, and shed light on their regulatory mechanisms, impact on disease states, and potential as therapeutic targets.
Submission deadline: 31 May 2024
Dr. Michael Pollak, co-Editor-in-Chief
Dr. Pollak is an internationally recognized expert in cancer endocrinology at the Lady Davis Institute for Medical Research of McGill University and a clinical oncologist at the Jewish General Hospital, Quebec, Canada.
"Cancer & Metabolism will provide a forum for rapid dissemination of research findings concerning metabolic factors that influence cancer risk and cancer pathophysiology, and cancer treatment. The scope of the Journal will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists."
Dr. Matthew G. Vander Heiden, co-Editor-in-Chief
Dr. Vander Heiden is Associate Director at the Koch Institute for Integrative Cancer Research at MIT. Extensively published in over 140 peer reviewed articles and book chapters, his research interests focus on the metabolic processes of cancer cells, including how glucose metabolism affects tumor growth and how these studies may lead to new developments in targeted cancer therapy. A renowned innovative researcher in his field, Dr. Vander Heiden received the 2017 Philip A. Sharp Innovation in Collaboration Award from Stand Up to Cancer (SU2C).
Dr. Costas Lyssiotis, Deputy Editor
Dr. Lyssiotis is the Maisel Research Professor of Oncology and an Associate Professor of Physiology and Medicine at the University of Michigan. The Lyssiotis research group studies the biochemical pathways and metabolic requirements that enable tumor survival and growth. This work spans the areas of cancer metabolism, the tumor microenvironment, and immunometabolism using and developing protocols in mass spectrometry-based metabolomics. Dr. Lyssiotis has published >150 peer reviewed research papers, and as a reflection of the impact of his work, he has been recognized as a highly cited researcher (top 1% across sciences) by Web of Science.
Kivanc Birsoy, The Rockefeller University, USA
Kevin Brindle, University of Cambridge, UK
Navdeep Chandel, Northwestern University, USA
Maralice Conacci Sorrell, University of Texas Southwestern Medical Center, USA
Lydia Finley, Memorial Sloan Kettering Cancer Center, USA
Christian Frezza, University Hospital Cologne, Germany
Richard G. Kibbey, Yale University School of Medicine, USA
Mioara Larion, National Cancer Institute, Center for Cancer Research, National Institutes of Health, USA
Jason Locasale, Duke University School of Medicine, USA
Christian Metallo, Salk Institute for Biological Studies, USA
Rachel Perry, Yale University School of Medicine, USA
Julie St-Pierre, University of Ottawa, Canada
Editorial Board Members:
Abass Alavi, University of Pennsylvania School of Medicine, USA
Lewis Cantley, Weill Cornell Medical College, USA
Peter Carmeliet, Vesalius Research Center, Belgium
Gina DeNicola, Moffitt Cancer Center, USA
Andrew Lane, Markey Cancer Center, USA
Sophia Lunt, Michigan State University, USA
Christian Metallo, University of California, San Diego Department of Bioengineering, USA
Gordon Mills, University of Texas M. D. Anderson Cancer Center, USA
Michael E Pacold, New York University Langone Health, USA
Thales Pappagiannokopoulos, NYU Grossman School of Medicine, USA
Jacques Pouyssegur, Institute of Research on Cancer and Aging, France
Joshua Rabinowitz, Princeton University, USA
Peter Ratcliffe, Nuffield Department of Clinical Medicine, UK
Jeffrey Rathmell, Duke University, USA
Jared Rutter, University of Utah School of Medicine, USA
Gregg Semenza, Johns Hopkins University School of Medicine, USA
Celeste Simon, University of Pennsylvania School of Medicine, USA
Bert Vogelstein, Johns Hopkins University School of Medicine, USA
Karen Vousden, Beatson Institute for Cancer Research, UK
Eileen White, The Cancer Institute of New Jersey, USA
Robert Gatenby, Moffitt Cancer Center, USA
Kun-Liang Guan, University of California, USA
Chi Van Dang, Editor Emeritus
Chi Dang is a professor, physician-researcher, renowned cancer biologist and hematologist-oncologist, who serves as director of the Abramson Cancer Center at the University of Pennsylvania.
"After several decades of profound advances in our understanding of the genetics and molecular biology of cancer, it has become self-evident that metabolism and bioenergetics are regulated by cancer genes and are intimately linked to the growth and survival of cancer cells. The obesity pandemic connected to increased cancer risk further underscore the importance of a richer understanding of cancer and organismal metabolism. In this regard, Cancer & Metabolism is launched uniquely to fulfill the needs of a burgeoning field which is at the crossroads of many scientific disciplines."
World Cancer Day 2021
The Editors of Cancer & Metabolism are delighted to highlight the following paper to mark the World Cancer Day:
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
Annual Journal Metrics
2022 Citation Impact
5.9 - 2-year Impact Factor
6.3 - 5-year Impact Factor
47 days submission to first editorial decision for all manuscripts (Median)
183 days submission to accept (Median)
1,349 Altmetric mentions
Springer Nature Oncology Portfolio
Discover the range of academic oncology titles at Springer Nature here.